The American Journal of Surgery
Volume 195, Issue 5 , Pages 604-610 , May 2008

Clinical utility of type 1 growth factor receptor expression in colon cancer

  • Sher-Ping Leung, M.D.

      Affiliations

    • Department of Surgery, St.Paul's Hospital, Vancouver, British Columbia, Canada
    • Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Obi L. Griffith, B.Sc.

      Affiliations

    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Michael Smith Genome Sciences Center, Vancouver, British Columbia, Canada
    • ,
  • Hamid Masoudi, M.D.

      Affiliations

    • Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Allen Gown, M.D.

      Affiliations

    • Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada
    • PhenoPath Laboratories, Seattle, WA, USA
    • ,
  • Steven Jones, Ph.D.

      Affiliations

    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Michael Smith Genome Sciences Center, Vancouver, British Columbia, Canada
    • ,
  • Terry Phang, M.D., F.R.C.S.C.

      Affiliations

    • Department of Surgery, St.Paul's Hospital, Vancouver, British Columbia, Canada
    • Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Sam M. Wiseman, M.D., F.R.C.S.C.

      Affiliations

    • Department of Surgery, St.Paul's Hospital, Vancouver, British Columbia, Canada
    • Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    • Genetic Pathology Evaluation Center at the Prostate Research Center, Vancouver General Hospital, Vancouver, British Columbia, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1-604-806-9108; fax: +1-604-806-9957.

Received 5 November 2007 ,Revised 30 December 2007

References 

  1. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000;13:3159–3167
  2. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;3:183–232
  3. Yarden Y. The EGFR family and its ligands in human cancer (Signalling mechanisms and therapeutic opportunities). Eur J Cancer. 2001;4:S3–S8
  4. Prigent SA, Lemoine NR. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Prog Growth Factor Res. 1992;4:1–24
  5. Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002;8:1065–1071
  6. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;1:37–46
  7. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;5:723–728
  8. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American joint committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;5:1331–1346
  9. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002;17:2258–2264
  10. Doger FK, Meteoglu I, Tuncyurek P, et al. Does the EGFR and VEGF expression predict the prognosis in colon cancer?. Eur Surg Res. 2006;6:540–544
  11. Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006;6:823–835
  12. Khorana AA, Ryan CK, Cox C, et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;4:960–968
  13. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;9:3069–3075
  14. Essapen S, Thomas H, Green M, et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 2004;2:241–248
  15. Osako T, Miyahara M, Uchino S, et al. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;6:548–555
  16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;4:337–345
  17. Rossi HA, Liu Q, Banner B, et al. The prognostic value of invariant chain (ii) and her-2/neu expression in curatively resected colorectal cancer. Cancer J. 2002;3:268–275
  18. Ishida H, Sadahiro S, Suzuki T, et al. c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol Rep. 2000;6:1229–1233
  19. Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and her-2/neu in colorectal adenocarcinomas. Cancer J. 2006;3:229–236
  20. Half E, Broaddus R, Danenberg KD, et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004;4:540–548
  21. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;8:895–904
  22. Kapitanović S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;4:1103–1113
  23. Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin) and irinotecan as therapy (A phase II trial). Cancer Invest. 2004;6:858–865
  24. Maurer CA, Friess H, Kretschmann B, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol. 1998;8:771–777
  25. Knosel T, Yu Y, Stein U, et al. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis. 2002;5:401–407
  26. Nakae S, Shimada E, Urakawa T. Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol. 1993;4:246–251
  27. Kapitanovic S, Radosevic S, Slade N, et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol. 2000;4:205–211
  28. Kountourakis P, Pavlakis K, Psyrri A, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006;6:46–54
  29. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;2:105–115
  30. Lenferink A, Pinkas-Kramarski R, van de Poll MLM, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998;12:3385–3397
  31. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999;2:305–314
  32. Buck E, Eyzaguirre A, Haley JD, et al. Inactivation of akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther. 2006;8:2051–2059
  33. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772–4777
  34. VanCutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist. 2006;9:1010–1017
  35. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;9:1803–1810

PII: S0002-9610(08)00100-1

doi: 10.1016/j.amjsurg.2007.12.032

The American Journal of Surgery
Volume 195, Issue 5 , Pages 604-610 , May 2008

Article Tools

* Image Usage & Resolution